Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES OPUS IN CONJUNCTION WITH ACQUISITION OF DREW TECHNOLOGIES
Mandate

VINGE ADVISES OPUS IN CONJUNCTION WITH ACQUISITION OF DREW TECHNOLOGIES

February 13, 2015

Vinge has advised Opus Group in connection with Opus Inspection, Inc.’s acquisition of all shares in Drew Technologies Inc., Michigan USA. Drew is a leading manufacturer of vehicle analysis equipment and diagnostics equipment for the vehicle inspection industry and OEM vehicle industry. The purchase price is USD 30 million (approximately SEK 250 million) plus a possible earn-out of USD 4.4 million (approximately SEK 36.5 million).  The transaction has been financed through a cash payment of USD 25 million (approximately SEK 209 million) and a directed issue in kind to the sellers of USD 5 million (approximately SEK 42 million). The transaction is expected to be completed within a thirty day period.

Vinge’s team consisted of responsible partner Anders Strid and associates Daniel Lennartsson and Frida Bäckergren.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025